Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2023
|
David Michael Williams EVP,Chief Info&Digital Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,205
+8.79%
|
$127,730
$106.72 P/Share
|
|
Feb 09
2023
|
Steven Mizell EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
5,000
-12.53%
|
$535,000
$107.0 P/Share
|
|
Feb 06
2023
|
Steven Mizell EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
4,436
-10.01%
|
$461,344
$104.25 P/Share
|
|
Feb 03
2023
|
Jennifer Zachary EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
75,436
-58.32%
|
$7,769,908
$103.17 P/Share
|
|
Feb 03
2023
|
Jennifer Zachary EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
75,436
+36.84%
|
$4,224,416
$56.04 P/Share
|
|
Jan 23
2023
|
David Michael Williams EVP,Chief Info&Digital Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,745
+13.68%
|
$190,205
$109.88 P/Share
|
|
Jan 23
2023
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Grant, award, or other acquisition
|
Direct |
2,091
+10.0%
|
$227,919
$109.88 P/Share
|
|
Jan 23
2023
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,846
+6.08%
|
$310,214
$109.88 P/Share
|
|
Jan 23
2023
|
Steven Mizell EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,192
+21.57%
|
$1,328,928
$109.88 P/Share
|
|
Jan 23
2023
|
Dean Y Li Executive VP & President, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
3,275
+14.11%
|
$356,975
$109.88 P/Share
|
|
Jan 23
2023
|
Jennifer Zachary EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
15,631
+22.47%
|
$1,703,779
$109.88 P/Share
|
|
Jan 23
2023
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
24,224
+8.18%
|
$2,640,416
$109.88 P/Share
|
|
Jan 23
2023
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
15,628
+9.24%
|
$1,703,452
$109.88 P/Share
|
|
Jan 23
2023
|
Caroline Litchfield EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,656
+8.09%
|
$289,504
$109.88 P/Share
|
|
Jan 23
2023
|
Michael A Klobuchar EVP - Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,651
+12.84%
|
$288,959
$109.88 P/Share
|
|
Jan 23
2023
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
17,495
+27.13%
|
$1,906,955
$109.88 P/Share
|
|
Jan 09
2023
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Open market or private sale
|
Direct |
83,994
-20.61%
|
$9,407,328
$112.67 P/Share
|
|
Jan 09
2023
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
83,994
+42.53%
|
$4,451,682
$53.06 P/Share
|
|
Dec 19
2022
|
Joseph Romanelli President, Human Health Int?l |
BUY
Open market or private purchase
|
Direct |
7
+0.03%
|
$763
$109.04 P/Share
|
|
Dec 13
2022
|
Joseph Romanelli President, Human Health Int?l |
BUY
Open market or private purchase
|
Direct |
56
+0.27%
|
$6,160
$110.96 P/Share
|
|
Dec 06
2022
|
Joseph Romanelli President, Human Health Int?l |
BUY
Open market or private purchase
|
Direct |
30
+0.15%
|
$3,270
$109.39 P/Share
|
|
Dec 05
2022
|
Joseph Romanelli President, Human Health Int?l |
BUY
Open market or private purchase
|
Direct |
107
+0.52%
|
$11,663
$109.54 P/Share
|
|
Dec 02
2022
|
Joseph Romanelli President, Human Health Int?l |
BUY
Open market or private purchase
|
Indirect |
59
+50.0%
|
$6,431
$109.67 P/Share
|
|
Nov 10
2022
|
Steven Mizell EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
15,000
-31.82%
|
$1,515,000
$101.42 P/Share
|
|
Nov 10
2022
|
Steven Mizell EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+24.14%
|
-
|
|
Nov 09
2022
|
Robert M Davis Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
167,613
-15.18%
|
$17,096,526
$102.84 P/Share
|
|
Nov 09
2022
|
Robert M Davis Chairman, CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
167,613
+28.76%
|
-
|
|
Nov 09
2022
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Open market or private sale
|
Direct |
1,795
-9.69%
|
$184,885
$103.21 P/Share
|
|
Nov 08
2022
|
Steven Mizell EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
20,000
-38.36%
|
$2,020,000
$101.0 P/Share
|
|
Nov 08
2022
|
Steven Mizell EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+27.72%
|
-
|
|
Nov 07
2022
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
235,769
-9.1%
|
$23,341,131
$99.31 P/Share
|
|
Nov 07
2022
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
235,769
+20.11%
|
-
|
|
Nov 07
2022
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Open market or private sale
|
Direct |
45,561
-71.09%
|
$4,510,539
$99.47 P/Share
|
|
Nov 07
2022
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Exercise of conversion of derivative security
|
Direct |
52,743
+23.45%
|
-
|
|
Nov 04
2022
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
235,000
-13.06%
|
$23,030,000
$98.81 P/Share
|
|
Nov 04
2022
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
235,000
+20.07%
|
-
|
|
Nov 03
2022
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
235,000
-12.88%
|
$23,030,000
$98.88 P/Share
|
|
Nov 03
2022
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
235,000
+20.07%
|
-
|
|
Nov 02
2022
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
300,000
-16.21%
|
$30,000,000
$100.04 P/Share
|
|
Nov 02
2022
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+13.94%
|
-
|
|
Nov 01
2022
|
Kenneth C Frazier Executive Chair |
SELL
Bona fide gift
|
Direct |
5,630
-0.27%
|
-
|
|
Nov 01
2022
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
300,000
-10.76%
|
$30,000,000
$100.29 P/Share
|
|
Nov 01
2022
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+22.97%
|
-
|
|
Oct 31
2022
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
300,000
-15.77%
|
$30,000,000
$100.42 P/Share
|
|
Oct 31
2022
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+22.97%
|
-
|
|
Oct 30
2022
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Payment of exercise price or tax liability
|
Direct |
450
-3.82%
|
$45,000
$100.77 P/Share
|
|
Oct 30
2022
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Exercise of conversion of derivative security
|
Direct |
913
+7.19%
|
$91,300
$100.77 P/Share
|
|
Oct 28
2022
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Open market or private sale
|
Direct |
164,557
-54.57%
|
$16,455,700
$100.26 P/Share
|
|
Oct 28
2022
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
164,557
+24.54%
|
-
|
|
Oct 28
2022
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
SELL
Open market or private sale
|
Direct |
100,292
-68.74%
|
$10,029,200
$100.1 P/Share
|